1. Market Research
  2. > Healthcare
  3. > Medical Supply Market Trends
  4. > Skin Ulcers – Pipeline Review, H1 2013

Skin Ulcers – Pipeline Review, H1 2013

  • April 2013
  • -
  • Global Markets Direct
  • -
  • 38 pages

Skin Ulcers – Pipeline Review, H1 2013

Summary

Global Markets Direct’s, 'Skin Ulcers - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Skin Ulcers, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Skin Ulcers. Skin Ulcers - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Skin Ulcers.
- A review of the Skin Ulcers products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Skin Ulcers pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Skin Ulcers.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Skin Ulcers pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Skin Ulcers - Pipeline Review, H1 2013
Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Skin Ulcers Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Skin Ulcers 7
Skin Ulcers Therapeutics under Development by Companies 9
Late Stage Products 10
Comparative Analysis 10
Mid Clinical Stage Products 11
Comparative Analysis 11
Skin Ulcers Therapeutics - Products under Development by Companies 12
Companies Involved in Skin Ulcers Therapeutics Development 13
Nanotherapeutics, Inc. 13
Henry Ford Health System 14
Galderma S.A. 15
RegeneRx Biopharmaceuticals, Inc. 16
EyeGene, Inc. 17
Skin Ulcers - Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Route of Administration 19
Assessment by Molecule Type 21
Drug Profiles 23
doxycycline - Drug Profile 23
Product Description 23
Mechanism of Action 23
RandD Progress 23
RGN-137 - Drug Profile 24
Product Description 24
Mechanism of Action 24
RandD Progress 24
HO/03/03 - Drug Profile 25
Product Description 25
Mechanism of Action 25
RandD Progress 25
Thymosin beta-4 - Drug Profile 27
Product Description 27
Mechanism of Action 27
RandD Progress 27
Skin Ulcers Therapeutics - Drug Profile Updates 28
Skin Ulcers Therapeutics - Dormant Products 30
Skin Ulcers - Product Development Milestones 31
Featured News and Press Releases 31
Feb 03, 2011: CardioVascular BioTherapeutics Submits FDA Application For 'Fast Track' Status For CVBT-141B 31
Jan 04, 2011: CardioVascular BioTherapeutics Announces Diabetic Wounds Drug Phase II Trial Data 31
Dec 08, 2010: DPT Receives FDA Approval To Commercially Manufacture Collagenase SANTYL Sterile Ointment 32
Jan 09, 2009: RegeneRx Reports Phase II Pressure Ulcer Trial Results 33
Sep 24, 2008: HealOr Announces $15 Million Investment Led By Mori Arkin To Heal Chronic Wounds 34
Sep 22, 2008: RegeneRx/Sigma-Tau Completes Patient Enrollment Of Second Phase II Clinical Trial With RGN-137 34
Aug 20, 2008: RegeneRx Completes Patient Enrollment Of First Phase II Clinical Trial 35
Apr 26, 2008: HealOr's Leading Drug HO/03/03 Receives Recognition From The Wound Healing Society In The SAWCandWHS 2008 Conference In San Diego 35
Nov 02, 2004: RegeneRx Gets Cleared To Initiate Phase II Clinical Trial With Tß4 For Chronic Pressure Ulcers 36
Appendix 37
Methodology 37
Coverage 37
Secondary Research 37
Primary Research 37
Expert Panel Validation 37
Contact Us 38
Disclaimer 38



List of Tables

Number of Products Under Development for Skin Ulcers, H1 2013 7
Products under Development for Skin Ulcers - Comparative Analysis, H1 2013 8
Number of Products under Development by Companies, H1 2013 9
Comparative Analysis by Late Stage Development, H1 2013 10
Comparative Analysis by Mid Clinical Stage Development, H1 2013 11
Products under Development by Companies, H1 2013 12
Nanotherapeutics, Inc., H1 2013 13
Henry Ford Health System, H1 2013 14
Galderma S.A., H1 2013 15
RegeneRx Biopharmaceuticals, Inc., H1 2013 16
Assessment by Monotherapy Products, H1 2013 18
Assessment by Stage and Route of Administration, H1 2013 20
Assessment by Stage and Molecule Type, H1 2013 22
Skin Ulcers Therapeutics - Drug Profile Updates 28
Skin Ulcers Therapeutics - Dormant Products 30



List of Figures

Number of Products under Development for Skin Ulcers, H1 2013 7
Products under Development for Skin Ulcers - Comparative Analysis, H1 2013 8
Products under Development by Companies, H1 2013 9
Late Stage Products, H1 2013 10
Mid Clinical Stage Products, H1 2013 11
Assessment by Monotherapy Products, H1 2013 18
Assessment by Route of Administration, H1 2013 19
Assessment by Stage and Route of Administration, H1 2013 20
Assessment by Molecule Type, H1 2013 21
Assessment by Stage and Molecule Type, H1 2013 22

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Keloids - Pipeline Review, H2 2016

Keloids - Pipeline Review, H2 2016

  • $ 2000
  • Company report
  • December 2016
  • by Global Markets Direct

Keloids - Pipeline Review, H2 2016 Summary Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Keloids – Pipeline Review, H2 2016, provides an overview of the Keloids ...

Wounds - Pipeline Review, H2 2016

Wounds - Pipeline Review, H2 2016

  • $ 2000
  • Company report
  • December 2016
  • by Global Markets Direct

Wounds - Pipeline Review, H2 2016 Summary Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Wounds – Pipeline Review, H2 2016, provides an overview of the Wounds (Dermatology) ...

Tissue Regenix Ltd - Product Pipeline Analysis, 2016 Update

Tissue Regenix Ltd - Product Pipeline Analysis, 2016 Update

  • $ 750
  • Company report
  • December 2016
  • by GlobalData

Summary Tissue Regenix Ltd (Tissue Regenix) is a medical technology company that offers replacement body parts from biological materials by using the dCELL technology platform. The company’s proprietary ...


ref:plp2013

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.